8-K: Aclarion, Inc. Receives Nasdaq Delisting Notice for Failure to Meet Minimum Bid Price Requirement

Aclarion, Inc. has received a notice from Nasdaq for not meeting the minimum bid price requirement of $1.00 per share, giving them 180 days to regain compliance.

Summary

• Aclarion, Inc. received a notice from Nasdaq on April 8, 2024, stating they are not in compliance with the $1.00 minimum bid price requirement for continued listing.
• The company's stock price closed below $1.00 for 30 consecutive business days ending April 5, 2024.
• Aclarion has 180 calendar days, until October 7, 2024, to regain compliance by having its stock price close at or above $1.00 for at least ten consecutive business days.
• If compliance is not achieved within the initial 180 days, Aclarion may be eligible for an additional 180-day period if they meet other listing requirements and notify Nasdaq of their intent to cure the deficiency, potentially through a reverse stock split.
• Failure to regain compliance could lead to delisting from the Nasdaq Capital Market, which the company could appeal.
• The company is monitoring its stock price and considering options to regain compliance.

Sentiment

Score: 3

Explanation: The document indicates a negative event (delisting notice) and potential risks, but also provides a path to compliance. The sentiment is therefore negative but not catastrophic.

Positives

• The notice does not result in the immediate delisting of the company's common stock.
• Aclarion has 180 days to regain compliance, providing time to address the issue.
• There is a possibility of an additional 180-day compliance period if certain conditions are met.
• The company can appeal a delisting determination to a Hearings Panel.

Negatives

• Aclarion's stock price has fallen below the required $1.00 minimum for 30 consecutive business days.
• The company is at risk of being delisted from the Nasdaq Capital Market if it does not regain compliance.
• The company may need to consider a reverse stock split to regain compliance.

Risks

• The company faces the risk of delisting from the Nasdaq Capital Market if it cannot raise its stock price above $1.00 within the given time frame.
• A reverse stock split, if implemented, could negatively impact shareholder value.
• The delisting notice could negatively affect investor confidence and the company's stock price.

Future Outlook

The company intends to monitor its stock price and is considering options to regain compliance with the minimum bid price requirement, including a potential reverse stock split.

Management Comments

• The company intends to monitor the closing bid price of its common stock and is considering its options to regain compliance with the Bid Price Requirement.
• The Companys receipt of the Notice does not affect the Companys business, operations or reporting requirements with the Securities and Exchange Commission.

Industry Context

This delisting notice highlights the challenges faced by companies with low stock prices, particularly in volatile market conditions. It is not uncommon for companies to receive such notices, and the response often involves efforts to increase the stock price or consider a reverse stock split.

Comparison to Industry Standards

• Many small-cap and micro-cap companies face similar challenges in maintaining Nasdaq listing compliance, particularly during periods of market volatility.
• Companies in the biotechnology and healthcare sectors, like Aclarion, can be particularly susceptible to stock price fluctuations based on clinical trial results, regulatory approvals, and market sentiment.
• Other companies that have received similar delisting notices have employed strategies such as reverse stock splits, capital raises, and improved financial performance to regain compliance.

Stakeholder Impact

• Shareholders may experience a decline in the value of their investment due to the delisting notice.
• Employees may be concerned about the company's future prospects.
• The company's reputation may be negatively impacted.

Next Steps

• Aclarion will monitor its stock price.
• Aclarion will consider options to regain compliance with the minimum bid price requirement.
• Aclarion may consider a reverse stock split.
• Aclarion may need to appeal a delisting determination if compliance is not achieved.

Key Dates

Keywords

delisting, Nasdaq, minimum bid price, compliance, stock price, reverse stock split, listing rule